Aclaris Therapeutics Inc’s recent filing unveils that its Director Mehra Anand acquired Company’s shares for reported $1.5 million on Nov 19 ’24. In the deal valued at $2.25 per share,666,666 shares were bought. As a result of this transaction, Mehra Anand now holds 710,030 shares worth roughly $2.14 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Leonard Braden Michael bought 206,025 shares, generating $256,357 in total proceeds. Upon buying the shares at $1.24, the 10% Owner now owns 14,250,000 shares.
Before that, Leonard Braden Michael bought 167,544 shares. Aclaris Therapeutics Inc shares valued at $216,400 were divested by the 10% Owner at a price of $1.29 per share. As a result of the transaction, Leonard Braden Michael now holds 14,043,975 shares, worth roughly $42.41 million.
Cantor Fitzgerald upgraded its Aclaris Therapeutics Inc [ACRS] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in mid November from “a Market perform” to “an Outperform”. Jefferies also remained covering ACRS and has increased its forecast on November 19, 2024 with a “Buy” recommendation from previously “Hold” rating. BTIG Research revised its rating on November 19, 2024. It rated ACRS as “a Buy” which previously was an “a Neutral”.
Price Performance Review of ACRS
On Monday, Aclaris Therapeutics Inc [NASDAQ:ACRS] saw its stock fall -6.21% to $3.02. Over the last five days, the stock has lost -22.76%. Aclaris Therapeutics Inc shares have risen nearly 187.62% since the year began. Nevertheless, the stocks have risen 184.91% over the past one year. While a 52-week high of $5.17 was reached on 11/19/24, a 52-week low of $0.80 was recorded on 01/12/24. SMA at 50 days reached $2.53, while 200 days put it at $1.54.
Levels Of Support And Resistance For ACRS Stock
The 24-hour chart illustrates a support level at 2.92, which if violated will result in even more drops to 2.82. On the upside, there is a resistance level at 3.19. A further resistance level may holdings at 3.37. The Relative Strength Index (RSI) on the 14-day chart is 45.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.60%. Stochastics %K at 3.51% indicates the stock is a buying.
How much short interest is there in Aclaris Therapeutics Inc?
A steep rise in short interest was recorded in Aclaris Therapeutics Inc stocks on 2024-11-29, growing by 71244.0 shares to a total of 2.48 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 2.41 million shares. There was a rise of 2.87%, which implies that there is a positive sentiment for the stock.
